Microtest has signed an agreement with UK-based biopharmaceutical company Antisoma to begin the aseptic manufacturing of AS1411, a new drug being developed for the treatment of various cancers. Under the terms of the agreement, Microtest will be responsible for the formulation and aseptic fill/finish of AS1411 material for upcoming Phase II trials. Microtest will also be responsible for stability testing of the AS1411 product.

“AS1411 is the first aptamer to be tested in cancer clinical trials. After successfully completing Phase I trials, we are now advancing to Phase II trials in renal cancer and AML. We are pleased to be supported in this work by expert specialist collaborators such as Microtest.” said Glyn Edwards, Antisoma’s chief executive officer.

“This agreement provides a strategic opportunity for us at Microtest to form a strong working partnership with an important category leader like Antisoma,” said Steve Richter, Microtest’s president. “Our flexibility, skills, and manufacturing expertise seamlessly compliment Antisoma’s scientific strength and clinical trial plans.”